Valuation : BICO Group AB

Market Cap 1.56B 163M 140M 132M 120M 225M 15.42B 226M 604M 7.89B 612M 599M 25.15B P/E 2026 *
-6.88x
P/E 2027 * -12.4x
Enterprise Value 1.49B 156M 134M 126M 115M 215M 14.73B 216M 578M 7.55B 585M 572M 24.04B EV / Sales 2026 *
0.92x
EV / Sales 2027 * 0.83x
Free-Float
69.88%
Yield 2026 *
-
Yield 2027 * -
1 day+35.29%
1 month+35.29%
3 months+8.83%
6 months+1.97%
Current year-15.85%
1 month 2.07
Extreme 2.07
2.07
Current year 1.52
Extreme 1.522
2.31
1 year 1.52
Extreme 1.522
2.73
3 years 1.52
Extreme 1.522
6.9
5 years 1.52
Extreme 1.522
64.5
10 years 0
Extreme 0
100
Manager TitleAgeSince
Chief Executive Officer 51 2026-08-31
Director of Finance/CFO 56 2026-02-28
Chief Operating Officer - 2026-01-06
Director TitleAgeSince
Director/Board Member 70 2019-12-17
Director/Board Member 37 2015-02-28
Director/Board Member - 2026-05-06
Change 5-day change 1-year change 3-year change Capi.($)
+35.29%-.--% - - 163M
-1.84%+0.50%+23.75%+16.44% 227B
-0.76%-0.17%+4.00%-16.82% 146B
-4.26%-4.58%-25.03%+18.15% 130B
-3.97%-3.72%-57.19%-14.07% 69.27B
-3.41%-4.08%+8.52%+17.51% 51.82B
+0.87%-0.94%-18.11%-12.85% 49.99B
-2.58%-1.98%+14.69%+28.92% 42.53B
-1.57%-0.58%+30.43%+53.09% 40.22B
-1.88%+3.33%+117.99%+35.15% 32.95B
Average +1.58%-0.93%+11.00%+13.95% 87.69B
Weighted average by Cap. -2.21%-1.41%+5.12%+9.43%

Financials

2026 *2027 *
Net sales 1.62B 169M 145M 137M 125M 234M 15.99B 234M 627M 8.19B 635M 621M 26.09B 1.69B 176M 151M 142M 130M 243M 16.62B 243M 652M 8.51B 660M 646M 27.11B
Net income -227M -23.67M -20.36M -19.15M -17.48M -32.69M -2.24B -32.79M -87.74M -1.15B -88.89M -86.94M -3.65B -126M -13.14M -11.3M -10.63M -9.7M -18.14M -1.24B -18.2M -48.7M -636M -49.34M -48.26M -2.03B
Net Debt -69M -7.19M -6.19M -5.82M -5.31M -9.94M -680M -9.97M -26.67M -348M -27.02M -26.43M -1.11B -166M -17.31M -14.89M -14M -12.78M -23.9M -1.64B -23.98M -64.17M -838M -65M -63.58M -2.67B
Logo BICO Group AB
BICO Group AB, previously Cellink AB is a Sweden-based company, which is primarily involved in the healthcare industry. The Company focuses on the application areas of bioprinting, multiomics, cell line development, and diagnostics. The Company develops and markets technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. The Company’s operations divided in two segments: The Industrial Solutions segment that offers products within precision dispensing and biosensor technology for industrial customers, which make a high-capacity contribution to customers production; and The Laboratory Solutions segment that offers 3Dprinters, single- cell and liquid- dispensing instruments as well as services and consumables related to these products.
Employees
554
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
22.15SEK
Average target price
29.00SEK
Spread / Average Target
+30.93%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!